Resveratrol, a natural phytoalexin, normalizes hyperglycemia in streptozotocin-nicotinamide induced experimental diabetic rats

Wild, 2004, Global prevalence of diabetes: estimates for the year 2000 and projections for 2030, Diabetes Care, 27, 1047, 10.2337/diacare.27.5.1047 McCarthy, 2001, Molecular diagnostics in monogenic and multifactorial forms of type 2 diabetes, Expert Rev Mol Diagn, 1, 403, 10.1586/14737159.1.4.403 Gerich, 2003, Clinical significance, pathogenesis, and management of postprandial hyperglycemia, Arch Intern Med, 163, 1306, 10.1001/archinte.163.11.1306 Kecskemeti, 2002, New trends in the development of oral antidiabetic drugs, Curr Med Chem, 9, 53, 10.2174/0929867023371427 Schuster, 2002, Diabetes mellitus, Clin Podiatr Med Surg, 19, 79, 10.1016/S0891-8422(03)00082-X Kahn, 2006, Mechanisms linking obesity to insulin resistance and type 2 diabetes, Nature, 444, 840, 10.1038/nature05482 Krentz, 2005, Oral antidiabetic agents: current role in type 2 diabetes mellitus, Drugs, 65, 385, 10.2165/00003495-200565030-00005 Nathan, 2006, Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes, Diabetes Care, 29, 1963, 10.2337/dc06-9912 Schlyer, 2006, I want a new drug: G-protein-coupled receptors in drug development, Drug Discov Today, 11, 481, 10.1016/j.drudis.2006.04.008 Witters, 2001, The blooming of the French lilac, J Clin Invest, 108, 1105, 10.1172/JCI14178 Bavaresco, 2003, Role of viticultural factors on stilbene concentrations of grapes and wine, Drugs Exp Clin Res, 29, 181 Soleas, 1997, Resveratrol: a molecule whose time has come? And gone?, Clin Biochem, 30, 91, 10.1016/S0009-9120(96)00155-5 Stewart, 2003, Resveratrol: a candidate nutritional substance for prostate cancer prevention, J Nutr, 133, 2440S, 10.1093/jn/133.7.2440S Siemann, 1992, Concentration of the phytoalexin resveratrol in wine, Am J Enol Vitic, 43, 49, 10.5344/ajev.1992.43.1.49 Juan, 2002, The daily oral administration of high doses of trans-resveratrol to rats for 28days is not harmful, J Nutr, 132, 257, 10.1093/jn/132.2.257 Renaud, 1992, Wine, alcohol, platelets, and the French paradox for coronary heart disease, Lancet, 339, 1523, 10.1016/0140-6736(92)91277-F Joe, 2002, Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines, Clin Cancer Res, 8, 893 Bhat, 2001, Biological effects of resveratrol, Antioxid Redox Signal, 3, 1041, 10.1089/152308601317203567 Virgili, 2000, Partial neuroprotection of in vivo excitotoxic brain damage by chronic administration of the red wine antioxidant agent, trans-resveratrol in rats, Neurosci Lett, 281, 123, 10.1016/S0304-3940(00)00820-X Gao, 2002, Disparate in vitro and in vivo antileukemic effects of resveratrol, a natural polyphenolic compound found in grapes, J Nutr, 132, 2076, 10.1093/jn/132.7.2076 Das, 1999, Cardioprotection of red wine: role of polyphenolic antioxidants, Drugs Exp Clin Res, 25, 115 Frankel, 1993, Inhibition of human LDL oxidation by resveratrol, Lancet, 341, 1103, 10.1016/0140-6736(93)92472-6 Pace-Asciak, 1995, The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease, Clin Chim Acta, 235, 207, 10.1016/0009-8981(95)06045-1 Fontecave, 1998, Resveratrol, a remarkable inhibitor of ribonucleotide reductase, FEBS Lett, 421, 277, 10.1016/S0014-5793(97)01572-X Chun, 1999, Resveratrol is a selective human cytochrome P450 1A1 inhibitor, Biochem Biophys Res Commun, 262, 20, 10.1006/bbrc.1999.1152 Rakieten, 1963, Studies on the diabetogenic action of streptozotocin (NSC-37917), Cancer Chemother Rep, 29, 91 Masiello, 1998, Experimental NIDDM: development of a new model in adult rats administered streptozotocin and nicotinamide, Diabetes, 47, 224, 10.2337/diabetes.47.2.224 Pulido, 1997, Gliclazide treatment of streptozotocin diabetic rats restores GLUT4 protein content and basal glucose uptake in skeletal muscle, Metabolism, 46, 10, 10.1016/S0026-0495(97)90310-3 Sasaki, 1972, Effect of acetic acid concentration on the colour reaction in the O-toluidine boric acid method for blood glucose estimation, Rinsh Kagaku, 1, 346 Drabkin, 1932, Spectrophotometric constants for common hemoglobin derivatives in human, dog and rabbit blood, J Biol Chem, 98, 719, 10.1016/S0021-9258(18)76122-X Nayak, 1981, A new colorimetric method for the estimation of glycosylated hemoglobin, Clin Chim Acta, 109, 267, 10.1016/0009-8981(81)90312-0 Lowry, 1951, Protein measurement with the Folin phenol reagent, J Biol Chem, 193, 265, 10.1016/S0021-9258(19)52451-6 Natelson, 1951, A rapid method for the estimation of urea in biologic fluids, Am J Clin Pathol, 21, 275, 10.1093/ajcp/21.3_ts.275 Brod, 1948, The renal clearance of endogenous “creatinine” in man, J Clin Invest, 27, 645, 10.1172/JCI102012 Caraway, 1963, Uric acid, 239, 10.1016/B978-1-4831-9685-5.50029-7 King, 1965, The transaminases: alanine and aspartate transaminases King, 1965, The hydorlases-acid and alkaline phosphatases Thulesen, 1997, Short-term insulin treatment prevents the diabetogenic action of streptozotocin in rats, Endocrinology, 138, 62, 10.1210/en.138.1.62 Virág, 2002, The therapeutic potential of poly (ADP-ribose) polymerase inhibitors, Pharmacol Rev, 54, 375, 10.1124/pr.54.3.375 Yang, 2002, Human beta cells are exceedingly resistant to streptozotocin in vivo, Endocrinology, 143, 2491, 10.1210/en.143.7.2491 Shima, 1998, A role of nicotinamide-induced increase in pancreatic beta-cell mass on blood glucose control after discontinuation of the treatment in partially pancreatectomized OLETF rats, Diabetes Res Clin Pract, 41, 1, 10.1016/S0168-8227(98)00061-8 Rodríguez, 1997, The increased skeletal muscle protein turnover of the streptozotocin diabetic rat is associated with high concentrations of branched-chain amino acids, Biochem Mol Med, 61, 87, 10.1006/bmme.1997.2585 Pepato, 1996, Role of different proteolytic pathways in degradation of muscle protein from streptozotocin-diabetic rats, Am J Physiol, 271, E340 Brodsky, 1998, Nutritional effects of dietary protein restriction in insulin-dependent diabetes mellitus, J Nutr, 128, 337S, 10.1093/jn/128.2.337S Giugliano, 2008, Glucose metabolism and hyperglycemia, Am J Clin Nutr, 87, 217S, 10.1093/ajcn/87.1.217S Yabe-Nishimura, 1998, Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications, Pharmacol Rev, 50, 21 Goldstein, 2004, Tests of glycemia in diabetes, Diabetes Care, 27, S91, 10.2337/diacare.27.7.1761 Howlett, 2008, Glycemic response and health: summary of a workshop, Am J Clin Nutr, 87, 212S, 10.1093/ajcn/87.1.212S Huebschmann, 2006, Diabetes and advanced glycoxidation end products, Diabetes Care, 29, 1420, 10.2337/dc05-2096 Singleton, 2003, Microvascular complications of impaired glucose tolerance, Diabetes, 52, 2867, 10.2337/diabetes.52.12.2867 Robertson, 2007, Estimation of beta-cell mass by metabolic tests: necessary, but how sufficient?, Diabetes, 56, 2420, 10.2337/db07-0742 Tominaga, 1999, Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study, Diabetes Care, 22, 920, 10.2337/diacare.22.6.920 Kilpatrick, 2000, Glycated haemoglobin in the year 2000, J Clin Pathol, 53, 335, 10.1136/jcp.53.5.335 Møller, 2008, Diabetes and protein metabolism, Diabetes, 57, 3, 10.2337/db07-1581 Sugden, 1991, Regulation of protein turnover in skeletal and cardiac muscle, Biochem J, 273, 21, 10.1042/bj2730021 Green, 1960, Protein catabolism and protein synthesis in perfused livers of normal and alloxan-diabetic rats, J Biol Chem, 235, 3202, 10.1016/S0021-9258(20)81337-4 Almdal, 1986, Increased capacity of urea synthesis in streptozotocin diabetes in rats, Diabetologia, 29, 812, 10.1007/BF00873222 Facchini, 1991, Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration, JAMA, 266, 3008, 10.1001/jama.266.21.3008 Modan, 1987, Elevated serum uric acid-a facet of hyperinsulinaemia, Diabetologia, 30, 713, 10.1007/BF00296994 Baynes, 1991, Role of oxidative stress in development of complications in diabetes, Diabetes, 40, 405, 10.2337/diabetes.40.4.405 Becker, 1993, Towards the physiological function of uric acid, Free Radic Biol Med, 14, 615, 10.1016/0891-5849(93)90143-I Travlos, 1996, Frequency and relationships of clinical chemistry and liver and kidney histopathology findings in 13-week toxicity studies in rats, Toxicology, 107, 17, 10.1016/0300-483X(95)03197-N Leclercq, 2007, Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences, J Hepatol, 47, 142, 10.1016/j.jhep.2007.04.002 Neuschwander-Tetri, 2003, Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference, Hepatology, 37, 1202, 10.1053/jhep.2003.50193 Elizabeth, 2005, Elevated liver function tests in type 2 diabetes, Clin Diabetes, 23, 115, 10.2337/diaclin.23.3.115 O'Brien, 1991, Regulation of gene expression by insulin, Biochem J, 278, 609, 10.1042/bj2780609 Grove, 1997, Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis, Hepatology, 26, 143, 10.1002/hep.510260119 El-Demerdash, 2005, Biochemical study on the hypoglycemic effects of onion and garlic in alloxan-induced diabetic rats, Food Chem Toxicol, 43, 57, 10.1016/j.fct.2004.08.012